Used in the treatment of osteoporosis in postmenopausal women, lasofoxifene tartrate helps reduce the risk of spinal and non-spinal fractures by acting as a selective estrogen receptor modulator (SERM). It mimics estrogen’s beneficial effects on bone density while minimizing negative effects on breast and uterine tissues. Additionally, it has shown potential in reducing the risk of certain types of breast cancer in postmenopausal women with osteoporosis. The compound is also being studied for its positive impact on cholesterol levels, contributing to cardiovascular health. Its oral bioavailability and tissue-selective action make it a valuable option in long-term management of menopausal health issues.